Announcements Trials
Browse Landscape

Phase

Phase 2 46Phase 3 14Phase NA 9Phase 1 6Phase 4 2Phase 2/3 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 2Sarcoma 2Tumor-Agnostic 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Pemetrexed 23Carboplatin 21Cisplatin 20pembrolizumab 15Docetaxel 14Paclitaxel 10Gemcitabine 8Drug Therapy 7Bevacizumab 7Gefitinib 5Radiotherapy 4Magnetic Resonance Spectroscopy 4Erlotinib Hydrochloride 4130-nm albumin-bound paclitaxel 4cemiplimab 3atezolizumab 3anlotinib 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cobimetinib 2auricularum 2aumolertinib 2apatinib 2Vemurafenib 2Topotecan 2Temozolomide 2Surgical Procedures, Operative 2Standard of Care 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Surgical Procedures, Operative × Thoracic × Clear all
NCT07076693 2025-07-22

Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC)

Shanghai Chest Hospital

Phase 2/3 Active not recruiting
97 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02326285 2018-01-23

NeoIntercal

AIO-Studien-gGmbH

Phase 2/3 Terminated
1 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡